Skip to main content
. 2010 Jan 29;116(1):8–22. doi: 10.1093/toxsci/kfq029

TABLE 4.

Changes in mRNA Expression of a Panel of Novel Renal Biomarkers in Kidneys of Male Wistar Rats Repeatedly Dosed with BI-2, BI-3, Gentamicin, or IMM125 for 1, 3, or 14 Days

Days of treatment BI-2 fold change (relative to control)
BI-3 fold change (relative to control)
Gentamicin fold change (relative to control)
IMM125 fold change (relative to control)
Gene 0 mg/kg 2.5 mg/kg 15 mg/kg 0 mg/kg 100 mg/kg 1000 mg/kg 0 mg/kg 25 mg/kg 75 mg/kg 0 mg/kg 30 mg/kg 100 mg/kg
Kim-1 (hepatitis A virus cellular receptor 1) 1 1.0 ± 0.2 0.8 ± 0.4 0.9 ± 0.4 1.0 ± 0.5 1.1 ± 0.8 0.9 ± 0.6 1.0 ± 0.5 0.9 ± 0.2 0.9 ± 0.3 1.0 ± 0.2 2.5 ± 1.3 3.4 ± 2.1*
3 1.0 ± 0.4 1.0 ± 0.3 0.9 ± 0.3 1.0 ± 0.4 0.9 ± 0.2 11.2 ± 23.5 1.0 ± 0.3 1.1 ± 0.3 2.1 ± 1.2 1.0 ± 0.3 2.9 ± 3.5 9.9 ± 6.0**
14 1.0 ± 0.3 0.8 ± 0.3 0.7 ± 0.1 1.0 ± 0.5 0.5 ± 0.2 392.5 ± 450.5 1.0 ± 0.2 91.2 ± 92.0 191.7 ± 100.8** 1.0 ± 0.3 3.1 ± 2.1 51.6 ± 29.9**
Clusterin 1 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.4 1.1 ± 0.5 1.0 ± 0.4 1.0 ± 0.2 1.1 ± 0.2 1.0 ± 0.1 1.0 ± 0.3 0.7 ± 0.3 0.6 ± 0.3
3 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.1 1.0 ± 0.2 1.0 ± 0.3 2.8 ± 4.4 1.0 ± 0.1 1.0 ± 0.1 1.3 ± 0.2 1.0 ± 0.1 2.0 ± 1.3 1.9 ± 1.2
14 1.0 ± 0.1 1.1 ± 0.2 0.9 ± 0.0 1.0 ± 0.4 1.3 ± 0.3 39.4 ± 43.1 1.0 ± 0.2 2.1 ± 1.2 1.6 ± 0.2 1.0 ± 0.4 1.7 ± 0.5 5.7 ± 3.0**
Lcn2 (NGAL) 1 1.0 ± 0.8 0.5 ± 0.1 0.6 ± 0.1 1.0 ± 0.6 0.8 ± 0.7 0.7 ± 0.4 1.0 ± 0.4 1.4 ± 0.2 1.1 ± 0.3 1.0 ± 0.9 2.6 ± 1.4 3.8 ± 2.4
3 1.0 ± 0.1 1.0 ± 0.1 0.9 ± 0.2 1.0 ± 0.4 1.0 ± 0.4 1.5 ± 1.5 1.0 ± 0.1 0.9 ± 0.4 1.0 ± 0.3 1.0 ± 0.2 3.6 ± 3.0 4.1 ± 2.6
14 1.0 ± 0.4 0.7 ± 0.1 0.7 ± 0.1 1.0 ± 0.3 1.7 ± 0.3 81.6 ± 151.4 1.0 ± 0.3 2.4 ± 1.8 4.9 ± 2.5* 1.0 ± 0.4 2.3 ± 1.2 6.2 ± 2.6**
Timp-1 1 1.0 ± 0.3 1.2 ± 0.5 1.3 ± 0.3 1.0 ± 0.4 0.9 ± 0.4 0.7 ± 0.3 1.0 ± 0.5 1.2 ± 0.6 1.2 ± 0.5 1.0 ± 0.4 2.7 ± 1.1 3.7 ± 2.1
3 1.0 ± 0.2 1.2 ± 0.2 1.1 ± 0.6 1.0 ± 0.2 0.8 ± 0.5 1.4 ± 1.5 1.0 ± 0.4 1.0 ± 0.4 1.2 ± 0.5 1.0 ± 0.5 2.9 ± 1.7 2.3 ± 1.4
14 1.0 ± 0.4 1.1 ± 0.3 1.1 ± 0.3 1.0 ± 0.3 1.0 ± 0.3 12.7 ± 12.1* 1.0 ± 0.5 1.9 ± 1.2 1.5 ± 0.6 1.0 ± 0.9 2.9 ± 1.6 5.5 ± 2.9**
OPN (secreted phosphoprotein 1) 1 1.0 ± 0.6 0.7 ± 0.2 0.8 ± 0.3 1.0 ± 0.5 1.1 ± 0.7 1.0 ± 0.5 1.0 ± 0.5 1.1 ± 0.7 1.0 ± 0.5 1.0 ± 1.0 1.5 ± 0.8 2.6 ± 2.1
3 1.0 ± 0.1 1.2 ± 0.3 0.9 ± 0.1 1.0 ± 0.3 1.0 ± 0.3 1.1 ± 0.8 1.0 ± 0.3 1.0 ± 0.3 1.1 ± 0.8 1.0 ± 0.2 2.6 ± 2.3 3.6 ± 2.4
14 1.0 ± 0.2 0.8 ± 0.2 0.8 ± 0.2 1.0 ± 0.3 1.3 ± 0.5 21.3 ± 21.6* 1.0 ± 0.0 2.4 ± 1.2 5.1 ± 1.6*** 1.0 ± 0.7 1.6 ± 0.6 4.8 ± 2.6**
HO-1 (HMOX1) 1 1.0 ± 0.1 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.6 1.4 ± 1.2 0.9 ± 0.6 1.0 ± 0.1 1.1 ± 0.3 0.8 ± 0.2 1.0 ± 0.4 3.0 ± 0.8 7.1 ± 5.8
3 1.0 ± 0.1 1.0 ± 0.3 1.0 ± 0.2 1.0 ± 0.2 1.2 ± 0.3 1.2 ± 0.3 1.0 ± 0.4 0.7 ± 0.2 0.9 ± 0.1 1.0 ± 0.3 11.8 ± 9.9 13.7 ± 9.4*
14 1.0 ± 0.2 1.0 ± 0.2 1.3 ± 0.2 1.0 ± 0.3 1.5 ± 0.3 7.1 ± 8.2 1.0 ± 0.1 1.8 ± 0.3* 3.4 ± 0.7*** 1.0 ± 0.5 13.4 ± 7.6** 14.7 ± 2.0**
Vimentin 1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.1 1.0 ± 0.4 1.0 ± 0.4 0.9 ± 0.3 1.0 ± 0.2 0.9 ± 0.1 0.9 ± 0.2 1.0 ± 0.3 1.3 ± 0.5 1.3 ± 0.4
3 1.0 ± 0.1 1.0 ± 0.2 0.9 ± 0.1 1.0 ± 0.1 1.0 ± 0.3 1.1 ± 0.3 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.1 1.0 ± 0.3 3.9 ± 2.5 3.3 ± 2.4
14 1.0 ± 0.1 0.9 ± 0.1 0.9 ± 0.0 1.0 ± 0.2 1.3 ± 0.4 3.4 ± 3.0 1.0 ± 0.2 1.0 ± 0.2 1.0 ± 0.1 1.0 ± 0.4 3.8 ± 1.8** 3.4 ± 0.6*

Note. Data are presented as mean ± SD of five individual animals per dose group. Statistical analysis was performed by ANOVA and Dunnett’s test.

*p < 0.05, **p < 0.01, and ***p < 0.001.